LV11321B - Isopropyl-(2-methoxyethyl)-4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate - Google Patents

Isopropyl-(2-methoxyethyl)-4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate Download PDF

Info

Publication number
LV11321B
LV11321B LVP-94-242A LV940242A LV11321B LV 11321 B LV11321 B LV 11321B LV 940242 A LV940242 A LV 940242A LV 11321 B LV11321 B LV 11321B
Authority
LV
Latvia
Prior art keywords
der
formula
chloro
cyano
och
Prior art date
Application number
LVP-94-242A
Other languages
English (en)
Latvian (lv)
Other versions
LV11321A (lv
Inventor
Meier Heinrich
Hartwig Wolfgang
Junge Bodo
Schohe-Loop Rudolf
Gao Zhan
Schmidt Bernard
Jonge Maarten De
Schuurman Teunis
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4342194A external-priority patent/DE4342194A1/de
Priority claimed from DE19944424677 external-priority patent/DE4424677A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of LV11321A publication Critical patent/LV11321A/xx
Priority to LVP-96-337A priority Critical patent/LV11737B/lv
Publication of LV11321B publication Critical patent/LV11321B/lv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
LVP-94-242A 1993-12-10 1994-12-09 Isopropyl-(2-methoxyethyl)-4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate LV11321B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
LVP-96-337A LV11737B (en) 1993-12-10 1996-08-16 2-chloro-3-cyano-benzaldehyde and method for preparing thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4342194A DE4342194A1 (de) 1993-12-10 1993-12-10 Halogen-phenyl-substituierte 1,4-Dihydropyridine
DE19944424677 DE4424677A1 (de) 1994-07-13 1994-07-13 Isopropyl-(2-methoxyethyl)-4-(2-chlor-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridin-3,5-dicarboxylat

Publications (2)

Publication Number Publication Date
LV11321A LV11321A (lv) 1996-06-20
LV11321B true LV11321B (en) 1996-12-20

Family

ID=25931956

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-94-242A LV11321B (en) 1993-12-10 1994-12-09 Isopropyl-(2-methoxyethyl)-4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate

Country Status (35)

Country Link
US (1) US5665740A (no)
EP (1) EP0657430B1 (no)
JP (1) JP3751041B2 (no)
KR (1) KR100332325B1 (no)
CN (2) CN1056606C (no)
AT (1) ATE180774T1 (no)
AU (1) AU686976B2 (no)
BG (1) BG62487B1 (no)
CA (1) CA2137525C (no)
CO (1) CO4290426A1 (no)
CU (1) CU22713A3 (no)
CZ (1) CZ286065B6 (no)
DE (1) DE59408350D1 (no)
DK (1) DK0657430T3 (no)
DZ (1) DZ1831A1 (no)
EE (1) EE03192B1 (no)
ES (1) ES2132308T3 (no)
FI (1) FI105681B (no)
GR (1) GR3030436T3 (no)
HR (1) HRP940967B1 (no)
HU (1) HU215593B (no)
IL (1) IL111922A (no)
LV (1) LV11321B (no)
MA (1) MA23392A1 (no)
MY (1) MY111976A (no)
NO (1) NO302362B1 (no)
NZ (1) NZ270087A (no)
PL (1) PL179973B1 (no)
RO (1) RO115800B1 (no)
SA (1) SA95160078B1 (no)
SK (1) SK282399B6 (no)
SV (1) SV1994000072A (no)
TN (1) TNSN94127A1 (no)
TW (1) TW412529B (no)
YU (1) YU48920B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1952824A1 (en) * 2003-11-21 2008-08-06 Memory Pharmaceuticals Corporation Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors
WO2008058234A2 (en) * 2006-11-08 2008-05-15 Memory Pharmaceuticals Corporation Pharmaceutical formulations for 1,4-dihyrdropyridine compounds having improved solubility
WO2019104041A1 (en) * 2017-11-21 2019-05-31 Michael Ohlmeyer Dihydropyridines for the treatment of cognitive impairment or traumatic brain injury

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1963188A1 (de) * 1969-12-17 1971-06-24 Bayer Ag Neue Cyanphenyl-1,4-dihydropyridinderivate
DE2117572C3 (de) * 1971-04-10 1980-03-20 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin ^-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
US3932646A (en) * 1971-04-10 1976-01-13 Farbenfabriken Bayer Ag Pharmaceutical compositions containing unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylate
DE2508181A1 (de) * 1975-02-26 1976-09-09 Bayer Ag 1,4-dihydropyridincarbonsaeurearal- kylester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2815578C2 (de) * 1978-04-11 1986-01-16 Bayer Ag, 5090 Leverkusen Neue pharmazeutische Verwendung von Nimodipin
DE2935451A1 (de) * 1979-09-01 1981-03-19 Bayer Ag, 5090 Leverkusen Optisch aktive 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arneimittel
DE3208628A1 (de) * 1982-03-10 1983-09-22 Bayer Ag, 5090 Leverkusen Neue verbindungen, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE3239273A1 (de) * 1982-10-23 1984-04-26 Bayer Ag, 5090 Leverkusen Tetrahydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US5137889A (en) * 1983-12-02 1992-08-11 Otsuka Pharmaceutical Co., Ltd. Dihydropyridine derivatives and process for preparing the same
DE3718398A1 (de) * 1987-06-02 1988-12-22 Troponwerke Gmbh & Co Kg Neue kombinationspraeparate mit antidepressiver wirkung
US5114946A (en) * 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
DE3806277A1 (de) * 1988-02-27 1989-09-07 Troponwerke Gmbh & Co Kg Verwendung von 1,4-dihydropyridin-derivaten
DE4011695A1 (de) * 1990-04-11 1991-10-17 Bayer Ag Verwendung von n-alkylierten 1,4-dihydropyridindicarbonsaeureestern als arzneimittel, neue verbindungen und verfahren zu ihrer herstellung
FR2671349B1 (fr) * 1991-01-09 1993-04-23 Lafon Labor Nouveaux derives de 1,4-dihydropyridine, leur procede de preparation et composition therapeutique les contenant.
DE4125271A1 (de) * 1991-07-31 1993-02-11 Bayer Ag Neue n-alkylierte 1,4-dihydropyridindicarbonsaeureester

Also Published As

Publication number Publication date
TW412529B (en) 2000-11-21
IL111922A0 (en) 1995-03-15
DZ1831A1 (fr) 2002-02-17
SA95160078B1 (ar) 2006-09-25
RO115800B1 (ro) 2000-06-30
YU48920B (sh) 2002-11-15
BG99249A (en) 1995-09-29
FI945777A0 (fi) 1994-12-08
NO944787L (no) 1995-06-12
SV1994000072A (es) 1995-08-09
NO944787D0 (no) 1994-12-09
JPH07242632A (ja) 1995-09-19
KR950017958A (ko) 1995-07-22
CZ286065B6 (cs) 2000-01-12
TNSN94127A1 (en) 1995-09-21
FI945777A (fi) 1995-06-11
CN1124258C (zh) 2003-10-15
DE59408350D1 (de) 1999-07-08
NZ270087A (en) 1996-08-27
HU215593B (hu) 1999-01-28
GR3030436T3 (en) 1999-09-30
KR100332325B1 (ko) 2002-09-04
YU71794A (sh) 1996-10-18
PL179973B1 (pl) 2000-11-30
HRP940967B1 (en) 1999-12-31
CU22713A3 (es) 1996-07-05
US5665740A (en) 1997-09-09
HU9403551D0 (en) 1995-02-28
IL111922A (en) 1999-05-09
LV11321A (lv) 1996-06-20
NO302362B1 (no) 1998-02-23
HUT70937A (en) 1995-11-28
CA2137525A1 (en) 1995-06-11
CN1244525A (zh) 2000-02-16
ES2132308T3 (es) 1999-08-16
HRP940967A2 (en) 1997-08-31
SK282399B6 (sk) 2002-01-07
CZ309394A3 (en) 1995-11-15
FI105681B (fi) 2000-09-29
SK151694A3 (en) 1995-07-11
CO4290426A1 (es) 1996-04-17
MA23392A1 (fr) 1995-07-01
JP3751041B2 (ja) 2006-03-01
EP0657430B1 (de) 1999-06-02
EP0657430A1 (de) 1995-06-14
MY111976A (en) 2001-03-31
AU8030694A (en) 1995-06-15
CA2137525C (en) 2005-07-12
PL306157A1 (en) 1995-06-12
CN1109874A (zh) 1995-10-11
AU686976B2 (en) 1998-02-12
CN1056606C (zh) 2000-09-20
BG62487B1 (bg) 1999-12-30
EE03192B1 (et) 1999-06-15
ATE180774T1 (de) 1999-06-15
DK0657430T3 (da) 1999-11-15

Similar Documents

Publication Publication Date Title
DE2248237C2 (de) Pleuromutilin-Derivate, deren Herstellung und pharmazeutische Zubereitung
DE3522604A1 (de) Neue feste formen von 2-(gamma)thoxy-4-(n-(1-(2-piperidino-phenyl)-3-methyl-1-butyl)-aminocarbonylmethyl)-benzoesaeure, diese formen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE69722858T2 (de) Intimale verdickungsinhibitoren
DE4243279A1 (de) Substituierte Triole
DE2549783B2 (de) Triglyceride mit entzündungshemmender Wirkung
DD235259A5 (de) Verfahren zur herstellung von 5,11-dihydro-11-[[(1-methyl-4-piperidinyl)amino]carbonyl]-6 h-dibenz[b,e]azepin-6-on und dessen salzen
EP0550895A1 (de) 4,13-Dioxabicyclo 8.2.1 tridecenon-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4430091A1 (de) Verwendung von N-substituierten Phenothiazinen
EP0316279A2 (de) Veresterte azacyclische Hydroxyverbindungen
DE2624789A1 (de) Eburnameninderivate und verfahren zu ihrer herstellung
LV11321B (en) Isopropyl-(2-methoxyethyl)-4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate
CH682400A5 (de) 1-(3-Chlorphenyl)-4-hydroxymethyl-7,8-dimethoxy-5H-2,3-benzodiazepin, seine Säureadditionssalze und diese enthaltende Arzneimittelpräparate sowie Verfahren zu deren Herstellung.
DE2632118A1 (de) Apovincaminolester und verfahren zu deren herstellung
DE2650013A1 (de) 1.4-dihydro-2.6-dimethyl-4-(3-nitrophenyl)-3.5-pyridindicarbonsaeure-isopropyl-(2-propoxy-aethyl)-ester, mehrere verfahren zu seiner herstellung sowie seine verwendung als peripherer vasodilatator
CH641162A5 (de) Verfahren zur herstellung neuer phenylazacycloalkane.
DE1695643A1 (de) Ester von 1-substituierten-3-substituierten Pyrrolidinmethanolen und Verfahren zu ihrer Herstellung
EP0595166B1 (de) 4-Heterocyclyl substituierte Dihydropyridine
DE69530830T2 (de) Lactacystinderivate
DE2719916A1 (de) Verfahren zur herstellung von 2,9-dioxatricyclo eckige klammer auf 4,3,1,0 hoch 3,7 eckige klammer zu decanen
DE2430510C3 (de) 16,17-Dihydroapovincaminsäureamide, Verfahren zu deren Herstellung und Arzneimittel, welche diese Verbingungen enthalten
DE2513197A1 (de) Cyclische verbindungen
DE3326364A1 (de) Epininester,verfahren zu ihrer herstellung und pharmazeutische mittel
EP0035641B1 (de) Cysteinderivate, Verfahren zur Herstellung derselben und diese enthaltende Arzneimittel
DD253616A5 (de) Verfahren zur herstellung von neuen pleunromutilinderivaten
EP0657432A1 (de) Phenyl-substituierte 1,4-Dihydropyridine mit cerebraler Aktivität